Maxygen, Inc.

Perseid Therapeutics LLC

Merck Sharp + Dohme Corp.

Altravax, Inc.

Stategics, Inc.

Astellas Pharma Gmbh

Ascendis Pharma Oncology Division A/s

Juha Punnonen

Steven Henry Bass

Erik E Karrer

Madan M Paidhungat

Steven J Chapin

Margaret Neighbors

Doris Apt

Alice M Brinkman

Willem P C Stemmer

Steven R Leong

Robert Gerald Whalen

Jeffrey R Spencer

Russell J Howard

Robert A Kastelein

Marie-Ange Buyse

Carlo Boutton

Bruno Dombrecht

Maribel Beaumont

Bjorn Victor

Timothy J Church

Edward P Bowman

Sridhar Viswanathan

Nicola Bisek

Torben Lessmann

Alexandra L L Lazetic

Tobias Voigt

Sebastian Stark

Samuel Weisbrod

James L Miller

Karen Lariosa-Willingham

Connie S Tettenborn

Chia-Chun Chang

David Vlerick

Drake LaFace

Alissa A Chackerian

Alexandra Lazetic

Jeffery Grein

Brent R Larsen

David B Rosen

Anandi Sawant

Jean Chia-Chun Chang

Edward Bowman

Lakshmanan Annamalai

Smita Mauze

David Bauche

Andrey Semyonov

Anne Wright

Dimitri Leonoudakis

Dmitri Leonoudakis

Yang Yang-malten

Lars Holten-andersen

Kennett SprogØe

Luis Zuniga

Anti-cancer combination therapies comprising a CTLA-4 blocking agent and a PD-1 blocking agent are disclosed. In particular, combination therapies are disclosed wherein the CTLA-4 blocking agent is an effector-silent anti-CTLA-4 antibody or effector-silent anti-CTLA-4 antibody fragment and the PD-1 blocking agent is an anti-PD-1 or anti-PD-L1 antibody, or antibody fragment thereof.

Anti-cancer combination therapies comprising CTLA-4 and PD-1 blocking agents

The present invention provides molecules, such as ISVDs and Nanobodies, that bind to CTLA4 or human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.

CTLA4 binders

The present invention provides multispecific molecules, e.g., comprising more than one ISVD or Nanobody, that bind to PD1 and CTLA4. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.

PD1/CTLA4 binders

Disclosed herein are erythropoietin-mimetic compounds of Formula I, which modulate the survival, function, or differentiation of, for example, kidney cells, neurons, erythroid cells, or other erythropoietin-responsive cells. The present invention also relates to compounds and methods that preferentially modulate cells expressing the tissue-protective erythropoietin receptor. The compounds of the invention are useful in preventing and treating diseases, such as anemia, organ injury, and diseases of the central nervous system, and as an adjunct to cellular treatments, such as stem cell therapies. 

Substituted triazolo-pyrimidine compounds for modulating cell proliferation, differentiation and survival

The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.

Recombinant dengue virus antigen comprising the capsid protein leader sequence, full-length prM protein, and full-length E protein

Substituted triazolo-pyrimidine compounds for modulating cell proliferation  differentiation and survival

The invention provides polypeptides and virus-like particles having, for example, an ability to induce an immune response to flaviviruses. The polypeptides can include C15, prM, and E polypeptide sequences.

The invention provides immunosuppressive polypeptides and nucleic acids encoding such polypeptides. In one aspect, the invention provides mutant CTLA-4 polypeptides and nucleic acids encoding mutant CTLA-4 polypeptides. Compositions and methods for utilizing such polypeptides and nucleic acids are also provided.

Immunosuppressive polypeptides and nucleic acids

Nucleic acids encoding novel chimeric C15/prM/E dengue virus immunogens prepared by DNA shuffling

Growing community of inventors

Belmont, CA, United States of America

Juha Punnonen